updates on mrx0518 pembro in patients with resistance to therapy
Published 3 years ago • 297 plays • Length 7:32Download video MP4
Download video MP3
Similar videos
-
8:04
mrx0518 pembro in patients with resistance to therapy
-
1:12
reactivating antitumor efficacy of anti-pd-1 therapy with mrx0518
-
1:31
mrx0518 combination therapy meets primary efficacy endpoint ahead of enrollment completion
-
1:38
future indications for mrx0518
-
1:20
resistance to immune checkpoint blockade in patients with cscc
-
1:53
mrx0518 modification of solid tumor microenvironment
-
3:48
overcoming resistance to immune checkpoint inhibitors in nsclc
-
1:21
keynote-921: pembrolizumab plus docetaxel in chemotherapy-naïve mcrpc
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
2:54
updated analysis of keynote-199: pembrolizumab for mcrpc previously treated with docetaxel
-
45:04
mvp reporting with oncoemr & mipspro
-
0:30
the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
-
1:19
what's on the horizon for the treatment of mpns?
-
1:04:09
drs. kuerer & mcarthur discuss the lastest #tnbc updates from #sso2022 - https://bit.ly/3ibs0zk
-
0:42
talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies
-
4:09
updates in urological cancer presented at esmo 2020
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
0:50
phase ii trial of ker-050 in patients with myelofibrosis
-
3:25
access to novel therapies in melanoma